Pre-made Imalumab benchmark antibody ( Whole mAb, anti-MIF therapeutic antibody, Anti-GIF/GLIF/MMIF Antibody) for drug discovery and mechanism of action (MOA) research
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Product Details
Pre-Made Imalumab biosimilar, Whole mAb, Anti-MIF Antibody: Anti-GIF/GLIF/MMIF therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Imalumab (BAX69) is an experimental monoclonal antibody against macrophage inhibitory factor (MIF), a cytokine known to exacerbate tumor growth. and as of January 2017 it is being tested in Phase IIa clinical trials for metastatic colorectal cancer. It was developed by Cytokine PharmaSciences and Baxalta, which was purchased by Shire Pharmaceuticals.
| Products Name (INN Index) | Pre-Made Imalumab biosimilar, Whole mAb, Anti-MIF Antibody: Anti-GIF/GLIF/MMIF therapeutic antibody |
|---|---|
| INN Name | Imalumab |
| Target | MIF |
| Format | Whole mAb |
| Derivation | Human |
| Species Reactivity | Human |
| CH1 Isotype | IgG1 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Phase-II |
| Est. Status | Discontinued |
| 100% SI Structure | 6foe:HL:AB |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2014 |
| Year Recommended | 2015 |
| Companies | Cytokine PharmaSciences,Baxalta,Shire,Takeda |
| Conditions Approved | NA |
| Conditions Active | NA |
| Conditions Discontinued | Solid tumours,Lupus nephritis,Colorectal cancer,Malignant ascites |
| Development Tech | NA |
| Previous Name | NA |
| Gm Offical Target Name | MIF |
| Package |
